Focus: Eurofarma Laboratórios is a Brazil-based pharmaceutical company focused on small molecules and generics across immunology, ophthalmology, and cardiovascular markets. The company operates primarily in the Latin American market with a concentrated revenue base.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Eurofarma Laboratórios to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship product generating 47% of company revenue; post-LOE generic formulation with mature market presence.
Help build intelligence for Eurofarma Laboratórios
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Eurofarma Laboratórios's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Branded NDA approaching patent expiration in 2028; second-largest revenue contributor at risk within 4 years.
Generic ANDA formulation in post-LOE phase; mature market product with limited growth trajectory.
NDA-based branded dermatology product approaching LOE with minimal revenue contribution.
NDA product with distinct mechanism (protein synthesis inhibitor) but no Part D spending data available.
ANDA formulation in pre-launch phase; represents near-term commercial opportunity in generic ophthalmology market.
ANDA product in post-LOE phase; legacy generic formulation with mature market positioning.
ANDA generic in post-LOE phase; part of portfolio's fluocinolone acetonide product ecosystem.
ANDA generic in post-LOE phase; additional fluocinolone acetonide formulation with stable market presence.
ANDA product in pre-launch development; represents near-term generic ophthalmology launch opportunity.
23 discontinued, 18 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo